


# Section of Hematology and Medical Oncology Newsletter



## In This Issue:

- Fellowship Match Results: 2
- New Staff: 3
- Awards: 3
- Publications: 4-6
- Upcoming Events: 7
- Holiday Wishes: 8



**Naser Jafari, PhD**, et al. are featured as the cover story for this week in Science Signaling:

Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes. The findings provide clues to how obesity and type 2 diabetes can promote cancer progression.

# Fellowship Match Results

## Appointment Year 2022

We are excited to share the results of our 2021 Match and look forward to working with all three of these impressive young doctors!



**Juan Chango, MD**  
University of Connecticut



**Lindsey Hildebrand, MD**  
Boston Medical Center



**Maya Srinivasan, MD**  
SUNY Downstate Medical Center

# New Staff



Christine VanDeWege

Christine VanDeWege has joined our team as the Director of Cancer Operations. Christine comes to us with over 30 years of Cancer experience, most recently serving as the Executive Director of Cancer Services at Beth Israel. She has extensive experience in cancer operations, research, finance and support services. In her previous roles, she has led the work to expand the physical footprint of cancer sites, improved patient experience and launched several multi-disciplinary initiatives.

# Awards



Laura Lowery, PhD

**Laura Lowery, PhD**, received a 2.2 million dollar R01 grant renewal from the NIH, entitled "Elucidating mechanistic connections between guidance signaling, microtubule regulation, and growth cone steering." This research focuses on the mechanisms that regulate early brain development, namely, how the intracellular machines that drive cell migration can be controlled.

# Publications



Vaishali Sanchorawala, MD

**Vaishali Sanchorawala, MD**, and colleagues published:

Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab.

Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab. Am J Hematol. 2021 Nov 05. doi: 10.1002/ajh.26399. Epub ahead of print. PMID: 34739735.

Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.

Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastiris E, Landau H, Mollee P, Wechalekar A, Palladini G. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2021 Nov 16:1-7. doi: 10.1080/13506129.2021.2002841. Epub ahead of print. PMID: 34783272.

Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis.

Furtado VF, Brauneis D, Weinberg J, Elhassan N, Sloan JM, Sanchorawala V. Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis. Bone Marrow Transplant. 2021 Nov 29. doi: 10.1038/s41409-021-01535-z. Epub ahead of print. PMID: 34845368.



# Publications



Jean-Antoine Ribeil, MD, PhD

**Jean-Antoine Ribeil, MD, PhD**, and collaborators published Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.

Kanter, J, Walters, M, Krishnamurti, L, Mapara, M, Kwiatkowski, J, Rifkin-Zenenberg, S, Aygun, B, Kasow, K, Pierciey, F, Bonner, M, Miller, A, Zhang, X, Lynch, J, Kim, D Ribeil, J-A, Asmal, M, Goyal, S, Thompson, A, Tisdale, J. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. The New England Journal of Medicine. 2021 Dec 12. DOI: 10.1056/NEJMoa2117175.



Kevan Hartshorn, MD

**Kevan Hartshorn, MD**, and collaborators published Viral Evasion of Innate Immune Defense: The Case of Resistance of Pandemic H1N1 Influenza A Virus to Human Mannose-Binding Proteins.

White, M, Nikolaidis, N, McCormack, F, Crouch, E, Hartshorn, K. Viral Evasion of Innate Immune Defense: The Case of Resistance of Pandemic H1N1 Influenza A Virus to Human Mannose-Binding Proteins. Frontiers in Microbiology. 2021 Dec 08. 12. 774711. 10.3389/fmicb.2021.774711.

# Publications



Chris Heaphy, PhD

**Chris Heaphy, PhD**, and collaborators published Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.

Dreijerink KMA, Hackeng WM, Singhi AD, Heaphy CM, Brosens LAA. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. J Pathol. 2021 Nov 9. doi: 10.1002/path.5834. Epub ahead of print. PMID: 34750813.



Naser Jafari, PhD

**Naser Jafari, PhD**, and collaborators published Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes.

Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, Pompa IR, Ennis CS, Mazzeo CS, Rabhi N, Farmer SR, Denis GV. Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes. Sci Signal. 2021 Nov 23;14(710):eabj2807. doi: 10.1126/scisignal.abj2807. Epub 2021 Nov 23. PMID: 34813359.



# Upcoming Section Events

12/15/21, 5:30pm, 72 E Concord St, 14th fl, Hiebert Lounge: Hem/Onc Holiday Party

12/16/21: Hem/Onc Special Lecture: Karen Axten, MD

<https://bostonmedicalcenter.zoom.us/j/91466284651pwd=UnNVVnNyekNia1FQWDVnNUVncUZjUT09>

Meeting ID: 914 6628 4651

Passcode: 442204

## Follow Us on Instagram!



Hematology & Medical Oncology is officially LIVE on Instagram!

Follow us at [@BMCHemOnc](https://www.instagram.com/BMCHemOnc)

If you or one of your patients would like to be featured, please submit a request at

<https://www.bumc.bu.edu/hematology/announcement-requests/>

## Available Career Opportunities as of December 2021:

- Clinical Investigator, Genitourinary Oncology Program
- Clinical Investigator, Hematology/Hematologic Malignancies
- Research Assistant
- Advanced Fellow in Sickle Cell Disease
- Clinical Research Nurse
- Clinical Research Coordinator





*Wishing you and your family a healthy  
and happy holiday season!*

*Best wishes for 2022!*



Boston University  
School of Medicine



EXCEPTIONAL CARE. WITHOUT EXCEPTION.